CD9 and glioblastoma: Nonetheless, the significant differences observed in EVs fromboth plasma (by UC and SEC) and CSF samples support the potentialof TNC+/CD9+ EV quantifications as clinicalbiomarkers for glioblastoma, across different methods and liquid biopsysources.